🟢 Compass Pathways is trading 11.32% up today on biotech M&A optimism

Compass Pathways is trading 11.32% up at $15.36 as biotech shares strengthened broadly on improving industry outlook and M&A optimism.

• Biotech ETF XBI is up 2.55%, while major U.S. indexes are also higher, supporting risk appetite.
• Compass Pathways is scheduled for a Deutsche Bank healthcare summit fireside chat on September 17.
• No new company-specific announcement clearly explains the move.